Evaluation of CD4+ T-cells and CD8+ T-cells in triple-negative invasive breast cancer

Jagtap, Sunil Vitthalrao

doi:10.4103/ijpm.ijpm_201_18

Cited by 34 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies, TILs were demonstrated to be closely related to clinical outcomes of BC patients, a systematic evaluation of these cell infiltrations may be able to guide the prognosis and appropriate treatment of breast cancer. [86][87][88] In this work, our findings further showed the expression of JAKs was associated to the infiltration of immune/ inflammatory cells. JAKs could be used as prognostic factors and immunotherapy targets in breast cancer.…”

supporting

confidence: 72%

Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer

Liu¹,

Wu²

2021

JIR

View full text Add to dashboard Cite

Background: Janus kinases (JAKs) are a family of non-receptor tyrosine kinases involved in multiple malignancies. However, clinical values of JAKs as prognostic markers and potential mechanism as molecular targets in breast invasive carcinoma (BC) are not completely clarified. Methodology: TIMER, UALCAN and GEPIA were used to assess the expression and methylation levels of JAKs in BC. Kaplan-Meier Plotter, bc-GenExMiner, SurvExpress, TRGAted, MethSurv, and SurvivalMeth were used to assess the multilevel prognostic significance of JAKs in breast cancer patients. And cBioPortal, TIMER, STRING, GeneMANIA, NetworkAnalysis, LinkedOmics, DAVID 6.8, and Metascape were applied for multilayer networks and functional enrichment analyses. Correlations between immune cell infiltrates/their gene markers and JAKs were evaluated by TIMER. Results: We first explored the expression and methylation level of JAKs in breast cancer and found significantly reduced JAK1 and JAK2 expression at mRNA and protein levels, significantly higher JAK3 protein expression, and significantly increased TYK2 expression at mRNA level but decreased at protein level. In addition, hypermethylation of JAK3 and TYK2 and hypomethylation of JAK1 were found in tumor samples. In terms of prognostic values of JAKs in BC patients, low transcriptional levels of JAK1, JAK2, JAK3, and TYK2 indicated worse OS/DMFS/PPS/RFS/DFS, inferior DFS, worse RFS, and shorter OS/DMFS/ RFS, respectively. The mRNA signature analysis showed that high-risk group had unfavorable OS/RFS/MFS. Low JAK2 protein level indicated unfavorable DSS/PFS in BC patients. Five CpGs of JAK1, four CpGs of JAK2, 20 CpGs of JAK3, and 13 CpGs of TYK2 were significantly associated with prognosis in BC patients. The DNA methylation signature analysis also suggested worse prognosis in the high-risk group. For potential biological roles of JAKs, interaction analyses, functional enrichment analyses for biological process, cellular component, molecular function, and KEGG pathway analyses of JAKs and their neighbor genes in BC were conducted. Kinase targets, gene-miRNA interactions, and transcription factor-gene interactions of JAKs were also identified. Furthermore, JAKs were found to be significantly related to immune infiltrates as well as the expression levels of multiple immune markers in BC. Conclusion: JAKs showed multilevel prognostic value and important biological roles in BC. They might serve as promising prognostic markers and possible targets in breast cancer.

show abstract

supporting

confidence: 72%

Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer

Liu¹,

Wu²

2021

JIR

View full text Add to dashboard Cite

show abstract

“…Experiments have shown that CD8+ T cells and CD4+ T cells play a role in the treatment of breast cancer, colon cancer, etc. ( 42 , 43 ), especially in melanoma ( 44 , 45 ). Enhanced dendritic actin network formation is clearly proven to have an effect on melanoma ( 46 ).…”

Section: Discussionmentioning

confidence: 99%

Development of an Immune-Related Gene Signature for Prognosis in Melanoma

et al. 2021

View full text Add to dashboard Cite

Melanoma remains a potentially deadly malignant tumor. The incidence of melanoma continues to rise. Immunotherapy has become a new treatment method and is widely used in a variety of tumors. Original melanoma data were downloaded from TCGA. ssGSEA was performed to classify them. GSVA software and the "hclust" package were used to analyze the data. The ESTIMATE algorithm screened DEGs. The edgeR package and Venn diagram identified valid immune-related genes. Univariate, LASSO and multivariate analyses were used to explore the hub genes. The "rms" package established the nomogram and calibrated the curve. Immune infiltration data were obtained from the TIMER database. Compared with that of samples in the high immune cell infiltration cluster, we found that the tumor purity of samples in the low immune cell infiltration cluster was higher. The immune score, ESTIMATE score and stromal score in the low immune cell infiltration cluster were lower. In the high immune cell infiltration cluster, the immune components were more abundant, while the tumor purity was lower. The expression levels of TIGIT, PDCD1, LAG3, HAVCR2, CTLA4 and the HLA family were also higher in the high immune cell infiltration cluster. Survival analysis showed that patients in the high immune cell infiltration cluster had shorter OS than patients in the low immune cell infiltration cluster. IGHV1-18, CXCL11, LTF, and HLA-DQB1 were identified as immune cell infiltration-related DEGs. The prognosis of melanoma was significantly negatively correlated with the infiltration of CD4+ T cells, CD8+ T cells, dendritic cells, neutrophils and macrophages. In this study, we identified immune-related melanoma core genes and relevant immune cell subtypes, which may be used in targeted therapy and immunotherapy of melanoma.

show abstract

“…31 Also, studies found that patients with breast cancer had the proportion of CD4 + and CD8 + T cells in the sentinel lymph node reversed, meaning metastasis of breast cancer and significantly associated with both relapse-free survival and overall survival. 30,31 Dezocine is widely used in perioperative anesthesia and postoperative analgesia in China due to its effective analgesic efficacy and fewer adverse events. 16,17 Dezocine is a partial μ receptor agonist and partial κ receptor agonist, which can inhibit the uptake of serotonin and epinephrine, similar to tramadol, and may have a similar…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of Dezocine and Sufentanil on Th1/Th2 Balance in Breast Cancer Patients Undergoing Surgery

Hu¹,

Liu²,

Wu³

et al. 2021

DDDT

View full text Add to dashboard Cite

Background: It is very important for breast cancer patients undergoing surgery to choose an opioid that has little effect on the immune system. The aim of this study is to compare the effects of dezocine or sufentanil on postoperative pain and Th1/Th2 balance in patients undergoing breast cancer surgery. Methods: Data from 92 breast cancer patients from January 2019 to July 2020 at Foshan Second People's Hospital (Guangdong, China) were analyzed. Sufentanil (SF) was used in group SF (n = 44) and dezocine (DE) in group DE (n = 48). The Visual Analog Scale (VAS) scores were assessed, and the percentages of Th1 cells and Th2 cells in peripheral blood were detected before anesthesia and at 2, 12, 24, and 48 hours after surgery. Results: There was no significant difference in the VAS scores between the two groups at 2, 24, and 48 hours after surgery (P > 0.05). The VAS scores at 12 hours after surgery in group DE were significantly lower than those in group SF with a statistically significant difference (P < 0.05). The percentage of Th1 cells in group DE at 2, 12, 24, and 48 hours after surgery was significantly lower than that in group SF (P < 0.05). The percentage of Th2 cells in group DE at 2, 12, 24, and 48 hours after surgery was significantly lower than that in group SF (P < 0.05). The Th1/Th2 ratio at 2, 12, 24, and 48 hours after surgery was significantly higher in group DE than that in group SF (P < 0.05). Conclusion: Dezocine for anesthesia induction and postoperative analgesia can maintain the balance of Th1/Th2 more stable than, with the same analgesia efficacy as, sufentanil during the early postoperative period in breast cancer patients undergoing surgery.

show abstract

Evaluation of CD4+ T-cells and CD8+ T-cells in triple-negative invasive breast cancer

Cited by 34 publications

References 8 publications

Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer

Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer

Development of an Immune-Related Gene Signature for Prognosis in Melanoma

Effects of Dezocine and Sufentanil on Th1/Th2 Balance in Breast Cancer Patients Undergoing Surgery

Contact Info

Product

Resources

About